Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00470054
Status:
COMPLETED
Last Update Posted:
2015-05-05
First Post:
2007-05-03
Brief Title:
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Study of Dasatinib NSC 732517 in Patients With Chemo-Sensitive Relapsed Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial is studying how well dasatinib works in treating patients with relapse small cell lung cancer Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Detailed Description:
PRIMARY OBJECTIVE I Determine the efficacy of dasatinib in patients with relapsed small cell lung cancer
SECONDARY OBJECTIVE II Determine the objective response rate complete and partial response in patients treated with this drug
III Determine the overall survival of patients treated with this drug IV Determine the toxicity of this drug in these patients
OUTLINE
Patients receive oral dasatinib twice daily on days 1-21 Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed at least every 3 months for 1 year and then every 6 months for 3 years
SECONDARY OBJECTIVE II Determine the objective response rate complete and partial response in patients treated with this drug
III Determine the overall survival of patients treated with this drug IV Determine the toxicity of this drug in these patients
OUTLINE
Patients receive oral dasatinib twice daily on days 1-21 Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed at least every 3 months for 1 year and then every 6 months for 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA031946 | NIH | CTEP | httpsreporternihgovquickSearchU10CA031946 |
| NCI-2009-00467 | REGISTRY | None | None |
| CDR0000543528 | None | None | None |
| CALGB 30602 | OTHER | None | None |
| CALGB-30602 | OTHER | None | None |
| P30CA014236 | NIH | None | None |